Adamas Pharmaceuticals

$4.38
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.08 (+1.86%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell ADMS and other stocks, options, and ETFs commission-free!

About ADMS

Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. The listed name for ADMS is Adamas Pharmaceuticals, Inc. Common Stock.

CEO
Neil F. McFarlane
Employees
136
Headquarters
Emeryville, California
Founded
2000
Market Cap
124.92M
Price-Earnings Ratio
Dividend Yield
Average Volume
130.03K
High Today
$4.44
Low Today
$4.23
Open Price
$4.30
Volume
100.09K
52 Week High
$7.45
52 Week Low
$1.90

Collections

ADMS Earnings

-$1.15
-$0.77
-$0.38
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Feb 25, After Hours

You May Also Like